Last reviewed · How we verify
NCT03565302
Beta2-adrenergic Agonism and Muscle Remodelling
NA trial testing Formoterol in Hypertrophy in 72 participants. Status unknown.
30 May 2021
Quick facts
| Lead sponsor | Morten Hostrup, PhD |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 72 |
| Start date | 25 June 2018 |
| Primary completion | 30 May 2021 |
| Estimated completion | 30 May 2021 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Formoterol (FORMOTEROL) — full drug profile →
- Terbutaline (TERBUTALINE) — full drug profile →
- Placebo
Conditions studied
- Hypertrophy — all drugs for Hypertrophy →
- Physiologic Hypertrophy — all drugs for Physiologic Hypertrophy →
- Physical Activity — all drugs for Physical Activity →
Sponsor
Morten Hostrup, PhD — full company profile →
Who can join
Adults 18 to 45, any sex, with Hypertrophy or Physiologic Hypertrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Inhaled formoterol impairs aerobic exercise capacity in endurance-trained individuals: a randomised controlled trial.
Jessen S, Lemminger A, Backer V, Fischer M, et al · · 2023 · cited 8× · PMID 37101738 · DOI 10.1183/23120541.00643-2022
Verify or expand the search:
- PubMed search for NCT03565302
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Formoterol
Trials testing the same drug.
- NCT06105671 — U-LABA/ICS Effects on Exercise Performance, Formoterol · NA · completed
- NCT04616261 — Beta2-adrenergic System and Training · NA · unknown
- NCT03573817 — A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Pa · Phase 3 · completed
- NCT03258749 — Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD · NA · unknown
- NCT04494321 — A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block · Phase 1 · completed
Other recruiting trials for Hypertrophy
Currently open trials in the same condition.
- NCT06573086 — Resistance Training, Detraining, and Retraining Study 2024 (TraDeRe2024) · NA · recruiting
- NCT05774444 — Investigating the Effects of Krill Oil and Krill Protein on Post-exercise Muscle Protein Metabolism · NA · recruiting
- NCT04514744 — Dynamic Proteomics and Integrated Rates of Muscle Protein Synthesis During an Acute Period of Loading and Unloading · NA · active not recruiting
Other Morten Hostrup, PhD trials
Trials by the same sponsor.
- NCT07421024 — Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle · Phase 2 · not yet recruiting
- NCT06188767 — Testosterone-induced Muscle Memory and Underlying Mechanisms · NA · recruiting
- NCT06067100 — U-LABA/ICS Effects on Exercise Performance, Indacaterol · NA · recruiting
- NCT06105671 — U-LABA/ICS Effects on Exercise Performance, Formoterol · NA · completed
- NCT06077019 — Role of Lung Function for Exercise Capacity in Well-trained Individuals · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03565302 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Morten Hostrup, PhD
- Last refreshed: 25 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03565302.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing